Gittenberger-de Groot A C, Strengers J L
Department of Anatomy and Embryology, Rijksuniversiteit Leiden, The Netherlands.
Int J Cardiol. 1988 May;19(2):153-66. doi: 10.1016/0167-5273(88)90076-9.
In the light of conflicting data in the literature on the relation between histopathology of the arterial duct and treatment with prostaglandin E1, we restudied our material. Special attention was paid to pathology of the duct not influenced by administration of prostaglandin E1. For this reason, three comparison groups (59 specimens) of non-treated ducts were evaluated. The results were compared with data from ducts obtained from 24 infants treated with prostaglandin E1. In agreement with our earlier findings, and with the results of Calder and her colleagues, there is indeed a marked increase in histopathology of the duct after administration of prostaglandin E1. The histopathology itself, however, is not specific for ducts treated with prostaglandin E1. It can also be found in the non-treated material. This has been previously described by others but had not been noted in our own previous work. The essential difference between those studies that confirmed an increase in pathology after treatment with prostaglandin E1 and those failing to find a marked effect is in the method of study. Changes were observed by those, including ourselves, who investigated complete sets of serial sections. The changes were not seen by those studying selected cross-sections from isolated parts of the duct or, at least in the cases treated with prostaglandin E1, sections taken at intervals.
鉴于文献中关于动脉导管组织病理学与前列腺素E1治疗之间关系的数据相互矛盾,我们重新研究了我们的资料。特别关注了不受前列腺素E1给药影响的导管病理学。因此,对三个未治疗导管的比较组(59个标本)进行了评估。将结果与24例接受前列腺素E1治疗的婴儿的导管数据进行了比较。与我们早期的研究结果以及考尔德及其同事的结果一致,使用前列腺素E1后导管的组织病理学确实有显著增加。然而,组织病理学本身并非前列腺素E1治疗导管所特有。在未治疗的材料中也能发现。这一点其他人之前已经描述过,但在我们之前的工作中并未注意到。那些证实使用前列腺素E1治疗后病理学增加的研究与那些未发现显著效果的研究之间的本质区别在于研究方法。包括我们自己在内,那些研究完整系列切片的人观察到了变化。而那些研究从导管孤立部分选取的选定横截面,或者至少在使用前列腺素E1治疗的病例中,间隔取样的切片的人则没有看到这些变化。